.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The National Health Authority (NHA) launched the AB PM-JAY Hackathon 2026 to revolutionize digital health in India. Consequently, this initiative seeks to automate the adjudication of nearly 50,000 daily claims under the nation's flagship health scheme. Currently, only 15 to 20 percent of these claims undergo automated processing. Therefore, the NHA requires advanced, package-agnostic solutions to improve speed and transparency for all stakeholders.
The primary goal of the AB PM-JAY Hackathon is to build a future-ready framework for claims management. Specifically, the NHA aims to leverage artificial intelligence for fraud detection and real-time verification. Furthermore, these digital solutions must integrate seamlessly with existing health infrastructure. Such innovations will reduce manual effort and accelerate processing timelines significantly. Ultimately, this transformation will deliver consistent outcomes for both patients and healthcare providers across the country.
Interested innovators, including students, startups, and developers, can register through the official portal until 13 April 2026. Additionally, the NHA will host a special three-part Masterclass Series starting on the registration deadline. These sessions will provide deep insights into the claims adjudication ecosystem and emerging innovation opportunities. Shortlisted teams will advance to an offline finale at the Indian Institute of Science, Bengaluru, in May 2026. Moreover, winners will receive substantial cash prizes and potential collaboration opportunities with the NHA.
Q1: What is the primary purpose of the AB PM-JAY Hackathon?
The hackathon aims to develop innovative, AI-driven solutions for auto-adjudication to handle the high volume of daily claims efficiently and transparently.
Q2: Who is eligible to participate in this event?
Students, researchers, developers, startups, and healthcare professionals from across India are eligible to register and present their ideas.
Q3: Where and when will the final event take place?
The grand finale will be held on 8-9 May 2026 at the prestigious Indian Institute of Science (IISc) in Bengaluru.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The NHA's AB PM-JAY Hackathon 2026 seeks AI-driven solutions to automate claims processing, enhancing transparency and efficiency in India's healthcare syst...
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
